ERBB2 and breast carcinoma: Patients with this subtype of breast cancer benefit from treatment with the anti-HER2 monoclonal antibody trastuzumab, both in the early and advanced stages, enjoying prolonged survival and lower toxicity (Lambertini et al., 2017).